Abstract
Availability of selective pharmacological tools enabled a great advance of our knowledge of cannabinoid receptor 2 (CB2) role in pathophysiology. In particular CB2 emerged as an interesting target for chronic pain treatment as demonstrated by several studies on inflammatory and neuropathic preclinal pain models. The mechanisms at the basis of CB2-mediated analgesia are still controversial but data are pointing out in two main directions: an effect on inflammatory cells and/or an action on nociceptors and spinal cord relay centers. In this review will be described the second messenger pathways activated by CB2 agonists, the data underpinning the analgesic profile of CB2 selective agonists and the mechanisms invoked to explain their analgesic action. Finally the ongoing clinical trials and the potential issues for the development of a CB2 agonist drug will be examined.
Keywords: Analgesia, agonist, neuropathic pain, signalling pathways
Mini-Reviews in Medicinal Chemistry
Title: Cannabinoid Type 2 Receptor as a Target for Chronic - Pain
Volume: 9 Issue: 1
Author(s): Massimiliano Beltramo
Affiliation:
Keywords: Analgesia, agonist, neuropathic pain, signalling pathways
Abstract: Availability of selective pharmacological tools enabled a great advance of our knowledge of cannabinoid receptor 2 (CB2) role in pathophysiology. In particular CB2 emerged as an interesting target for chronic pain treatment as demonstrated by several studies on inflammatory and neuropathic preclinal pain models. The mechanisms at the basis of CB2-mediated analgesia are still controversial but data are pointing out in two main directions: an effect on inflammatory cells and/or an action on nociceptors and spinal cord relay centers. In this review will be described the second messenger pathways activated by CB2 agonists, the data underpinning the analgesic profile of CB2 selective agonists and the mechanisms invoked to explain their analgesic action. Finally the ongoing clinical trials and the potential issues for the development of a CB2 agonist drug will be examined.
Export Options
About this article
Cite this article as:
Beltramo Massimiliano, Cannabinoid Type 2 Receptor as a Target for Chronic - Pain, Mini-Reviews in Medicinal Chemistry 2009; 9 (1) . https://dx.doi.org/10.2174/138955709787001785
DOI https://dx.doi.org/10.2174/138955709787001785 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Polymorphisms of Human N-Acetyltransferases and Cancer Risk
Current Drug Metabolism Anti-Proliferative Effects of Novel Glyco-Lipid-Arsenicals (III) on MCF-7 Human Breast Cancer Cells
Medicinal Chemistry Invasive Aspergillosis in Children and Adolescents
Current Pharmaceutical Design HtrA Serine Proteases as Potential Therapeutic Targets in Cancer
Current Cancer Drug Targets Bisphosphonate Therapy in the Treatment of Multiple Myeloma
Current Pharmaceutical Design The Need for Diagnostic Criteria in Systemic Vasculitis
Current Immunology Reviews (Discontinued) General Principles for the Treatment of Non-Infectious Uveitis
Inflammation & Allergy - Drug Targets (Discontinued) Histone Deacetylase Inhibitors: An Attractive Strategy for Cancer Therapy
Current Medicinal Chemistry Prophylaxis of Cancer
Current Cancer Therapy Reviews Mitochondrial Tolerance to Drugs and Toxic Agents in Ageing and Disease
Current Drug Targets Cellular Therapy of Lysosomal Storage Disorders: Current Status and Future Prospects
Current Pediatric Reviews Receptor Tyrosine Kinases Take a Direct Route to Mitochondria: An Overview
Current Protein & Peptide Science Targeted Therapy for Advanced Urothelial Cancer of the Bladder: Where Do We Stand?
Anti-Cancer Agents in Medicinal Chemistry Medicinal Research Progress of Natural Coumarin and its Derivatives
The Natural Products Journal Asthma, Allergy and Chemokines
Current Drug Targets MiRNAs in Human Cancers: The Diagnostic and Therapeutic Implications
Current Pharmaceutical Design Ellipticine, its Derivatives: Re-evaluation of Clinical Suitability with the Aid of Drug Delivery Systems
Current Cancer Drug Targets Distinctive Cellular Roles for Novel Protein Kinase C Isoenzymes
Current Pharmaceutical Design Eph/Ephrin Membrane Proteins: A Mammalian Expression Vector pTIg- BOS-Fc Allowing Rapid Protein Purification
Protein & Peptide Letters Role of the Bone Marrow Microenvironment in Drug Resistance of Hematological Malignances
Current Medicinal Chemistry